A Randomised, Double Blind, Placebo-controlled, Multicenter Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061

Trial Profile

A Randomised, Double Blind, Placebo-controlled, Multicenter Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Lersivirine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Oct 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 23 Oct 2009 Results were reported in AIDS.
    • 29 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top